论文部分内容阅读
Background: Androgen-deprivation therapy(ADT)has been the treatment for metastatic prostate cancer for more 75 years.We assessed whether concomitant treatment with ADT added to docetaxel would result in patients newlydiagnosed metastatic hormone-sensitive prostate cancer for longer overall survival.Methods and Materials: Since August 2014,14 patients with metastatic,hormone-sensitive prostate cancer received ADT plus docetaxel(at a dose of 75 mg per square meter of body-surface area every 3 weeks for six cycles).The primary objective was to test the hypothesis that the median overall survival would be more longer among patients receiving docetaxel added to ADT early during therapy.Results: After six cycles of docetaxel added to ADT therapy,four patients PSA level reduced less than 0.2 ng/mL and observe the withdrawal;one patient PSA rise to 4 ng/mL received ADT treatment again;one patient had grade 3 blood toxicity.None grade 4 blood toxicity occurred.Conclusions: Patients with hormone-sensitive metastatic prostate cancer overall survival prolonged significantly after ADT + D therapy;6-cycle chemotherapy were recommended;the benefit for docetaxel therapy was found to be more apparent in the high-volume metastatic group.